GILDGILEAD SCIENCES, INC.
Biological Products, (no Diagnostic Substances)
- Revenue
- $29.4B
- 2.4% YoY
- Operating margin
- 34.0%
- 489% YoY
- EBITDA
- $10.4B
- 409% YoY
- Market cap
- —
- Employees
- —
- Net debt / EBITDA
- 2.3×
- $23.6B net debt
- AI in 10-K
- —
Red flags 0 of 9
- TSR below peersClear—3+ of last 5 years
- High CEO pay despite TSRClear—Median CEO pay ≥ $15M and TSR flag
- Active 13DClear0 filingsActive-intent 13D in 18 months
- Net insider sellingClear$0 netNet sales over $10M in 12 months
- Earnings not backed by cashClear118% of net incomeCash flow under 80% of net income
- Dilutive SBCClear3% of revenueOver 10% of revenue
- Payouts exceed cash flowClear59% of cash flowBuybacks + dividends over cash flow
- Goodwill-heavyClear16% of assetsOver 40% of assets
- Shareholder dissentClear—Any vote under 80% support
Financials
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | YoY |
|---|---|---|---|---|---|---|
| Revenue | $27.3B | $27.3B | $27.1B | $28.8B | $29.4B | 2.4% |
| Operating income | $9.9B | $7.3B | $7.6B | $1.7B | $10.0B | 503% |
| Net income | $6.2B | $4.6B | $5.7B | $480M | $8.5B | 1673% |
| Operating cash flow | $11.4B | $9.1B | $8.0B | $10.8B | $10.0B | 7.5% |
| Capex | $579M | $728M | $585M | $523M | $563M | 7.6% |
| Stock-based comp | $635M | $637M | $766M | $835M | $894M | 7.1% |
| Buybacks | $546M | $1.4B | $1.0B | $1.1B | $1.9B | 67% |
| Dividends | $3.6B | $3.7B | $3.8B | $3.9B | $4.0B | 2.2% |
Deal filings
None.
13D filers
None on file.
Insider trading
- Open-market buys, 12 mo
- $0 · 0
- Open-market sells, 12 mo
- $4M · 8
- Net
- −$4M
Pay vs performance
No pay-versus-performance disclosure yet.